QuidelOrtho QDEL
NASDAQ QDEL
$10.77 +0.39 (+3.76%)
At close: Oct 2, 2026 · 4:00 PM EDT

QuidelOrtho (QDEL) Asset Writedowns and Impairment (2023 - 2025)

Updated

QuidelOrtho (QDEL) reported Asset Writedowns and Impairment of $700.7 million for FY2025, down 61.6% from $1.82 billion in FY2024.

Analysis

QuidelOrtho (QDEL) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends

Dating back to FY2022, QuidelOrtho's Asset Writedowns and Impairment record includes 4 years.

  • Asset Writedowns and Impairment has a three-year compound annual growth rate of 530.2% (FY2022 to FY2025).
  • Five-year annual Asset Writedowns and Impairment spans a low of $2.8 million in FY2022 and a high of $1.82 billion in FY2024.
  • According to Business Quant data, Asset Writedowns and Impairment came in at $1.82 billion in FY2024, $4.5 million in FY2023 (+60.7%) and $2.8 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 242.18 Bn 221.33 Bn 4.88 Bn
2 Abbott Laboratories 168.71 Bn 139.79 Bn 7.27 Bn
3 Danaher 150.46 Bn 134.27 Bn 3.61 Bn
4 Intuitive Surgical 138.71 Bn 118.26 Bn 1.96 Bn
5 Medtronic 110.54 Bn 76.41 Bn 6.34 Bn
6 Stryker 105.66 Bn 91.78 Bn 4.50 Bn
7 Boston Scientific 61.74 Bn 56.75 Bn 3.85 Bn
8 Edwards Lifesciences 49.09 Bn 33.21 Bn 1.35 Bn
9 Becton Dickinson 48.16 Bn 45.31 Bn 2.32 Bn
10 QuidelOrtho 735.59 Mn 203.89 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 28, 2025 9.70 Mn
Dec 29, 2024 78.70 Mn
Jun 30, 2024 56.90 Mn
Mar 31, 2024 1.74 Bn
Dec 31, 2023 1.30 Mn
Oct 1, 2023 2.20 Mn
Jul 2, 2023 500,000.00
API Access

QuidelOrtho Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=QDEL&period=max&api_key=YOUR_API_KEY